Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. The company's proprietary Transient Permeability Enhancer (TPEÂŽ) technology platform is designed to enable the intestinal absorption of molecules that would otherwise have limited intestinal bioavailability. The company is developing octreotide capsules (conditionally trade named MycapssaÂŽ) for the potential maintenance treatment of adult patients with acromegaly. The company completed an international Phase 3 trial of octreotide capsules, the results of which have been published in the Journal of Clinical Endocrinology and Metabolism. Source
No articles found.
Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transfo...
Jounce Therapeutics is a clinical stage immunot...
The Healthereum Patient Behavior Management platform is a full cycle communication...
The Healthereum Patient Behavior Management pla...
Check-Cap is a clinical-stage medical diagnostics company developing C-ScanÂŽ, the...
Check-Cap is a clinical-stage medical diagnosti...
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the disco...
Aerie Pharmaceuticals is an ophthalmic pharmace...
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company foc...
Founded in November 2012, ObsEva is a clinical-...
BiondVax is an innovative biopharmaceutical company developing a universal flu vac...
BiondVax is an innovative biopharmaceutical com...
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...
Evelo Biosciences, Inc. is a clinical stage bio...
Join the National Investor Network and get the latest information with your interests in mind.